Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Abstract: The present invention relates to a methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.

Abstract: Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of factor IX and liquid formulations of factor IX suitable for storage and administration.

Abstract: Provided by the present invention are novel methods of protein recovery and purification methods and more specifically novel methods for the recovery and purification thioredoxin fusion proteins, especially of IL-11.

Abstract: Provided by the present invention are novel methods of factor IX protein recovery and purification.

Abstract: Purified Bone Morphogenetic Protein-10 (BMP-10) proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-10 proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.

Abstract: Compositions of proteins with chondrocyte and cartilaginous tissue inducing activity, as well as method of using those compositions, are disclosed. The compositions comprise one or more proteins of the transforming growth factor-.beta. (TGF-.beta.) superfamily of proteins, particularly bone morphogenetic proteins (BMPs), in combination with parathyroid hormone related polypeptide (PTHrP) or an equivalent PTH-like polypeptide. The compositions and methods are useful in the treatment of osteoarthritis, cartilage defects and in related tissue repair.

Abstract: Purified Bone Morphogenetic Protein-11(BMP-11) proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the proteins may be useful for the induction of bone, cartilage and/or other connective tissue.

Abstract: Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of minor metastases, asthma, preeclampsia, and allergic disorders such as rhinitis, conjunctivitis, and urticaria.

Abstract: Provided are nucleic acid sequence sequences encoding enterokinase activity, the expression products thereof, and methods for using same.

Abstract: Provided is a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to a DNA sequence encoding a second peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. The fusion molecule may be modified to introduce one or more metal-binding/chelating amino-acid residues to aid in purification. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.

Abstract: Provided by the present invention are novel methods of detecting ligand interactions, as well as regents useful in the method, including DNA and host cells; and more specifically relates to novel methods for the detection of protein/protein interactions and their application in epitope mapping and the study of ligand/receptor interactions. Also provided are vaccines and kits comprising the expression products and host cells of the invention.

Abstract: Provided by the present invention is a method for treating von Willebrand Disease (vWD) by administering IL-11. The present invention relates generally to novel methods for treating bleeding disorders and more specifically relates to methods for treating von Willebrand Disease (vWD) hemophilia A, and various hemostatic disorders such as uremia, cirrhosis, congenital platelet defects, congenital and acquired storage pool deficiency, patients with unexplained prolongations of bleeding time, as well as prophylactic treatment before surgeries.

Abstract: Provided are porcine factor VIII nucleotide sequences and hybrid sequences encoding human/porcine chimeric factor VIII-type procoagulant proteins. DNAs encoding such chimeric factor VIII-type procoagulant proteins, pharmaceutical compositions containing such chimeric factor VIII-type procoagulant proteins, and methods of treating hemophilia using such chimeric factor VIII-type procoagulant proteins are also provided.

Abstract: A method for reducing damage or depletion of gut epithelial cells (e.g., as a result of radiation therapy or chemotherapy) by administration of one or more of the following cytokines: interleukin 11 (IL-11), interleukin 6 (IL-6), leukemia inhibitory factor/cholinergic differentiation factor (LIF/CDF), oncostatin M (OSM), or ciliary neurotrophic factor (CNTF).

Abstract: This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same. The variants of this invention are characterized by modification of one or more specific proteolytic cleavage sites encompassing the arginine residues at positions 226, 336, 562, 740, 776, 1313, 1648, or 1721. The variants possess similar procoagulant activity to that of human Factor VIII:c.

Abstract: A method of restoring damaged or depleted cell populations by treating the patient with cytokines, particularly IL-11 and IL-6.

Abstract: This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same.

Abstract: Provided by the present invention is a novel cytokine, IL-9, an approximately 144 amino acid protein, characterized by an apparent molecular weight of between 20 to 30 kD and having biological activity in an MO7E cell assay. The cytokine can be used, inter alia, as a mitogen, as an antigen, and to regulate hematopoiesis.